Zacks: Brokers expect IsoPlexis Co. (NASDAQ: ISO) to post -$0.59 per share profit
Wall Street brokers expect IsoPlexis Co. (NASDAQ: ISO – Get Rating) to post earnings per share of ($0.59) for the current quarter, reports Zacks Investment Research. Zero analysts released earnings estimates for IsoPlexis, with the highest EPS estimate being $0.56 and the lowest estimate $0.62. The company is expected to release its next quarterly earnings report on Monday, January 1.
According to Zacks, analysts expect IsoPlexis to report full year earnings of ($2.41) per share for the current fiscal year, with EPS estimates ranging from ($2.51) to ($2. $.32). For the next fiscal year, analysts expect the company to post earnings of ($2.05) per share, with EPS estimates ranging from ($2.25) to ($1.65). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts who provide coverage for IsoPlexis.
ISO has been the subject of several recent research reports. Zacks Investment Research downgraded IsoPlexis from a “buy” rating to a “hold” rating in a Wednesday, February 16 research report. SVB Leerink reduced its target price on IsoPlexis from $20.00 to $15.00 and set an “outperform” rating on the stock in a Thursday, January 27 report. Finally, Morgan Stanley cut its price target on IsoPlexis from $17.00 to $12.00 and set an “overweight” rating on the stock in a Tuesday, Feb. 15 research note. One equity research analyst gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $14.44.
NASDAQ ISO opened at $2.17 on Friday. IsoPlexis has a 1-year minimum of $2.12 and a 1-year maximum of $16.95. The company has a 50-day moving average price of $3.92. The company has a quick ratio of 9.88, a current ratio of 11.67 and a leverage ratio of 0.22.
Several major investors have recently changed their positions within the ISO. Northpond Ventures LLC acquired a new stock position in IsoPlexis in the fourth quarter worth $80,920,000. Perceptive Advisors LLC acquired a new position in IsoPlexis in the fourth quarter worth approximately $37,637,000. BlackRock Inc. acquired a new position in IsoPlexis in the fourth quarter worth approximately $22,579,000. Ally Bridge Group NY LLC acquired a new equity stake in IsoPlexis during the fourth quarter valued at approximately $16,267,000. Finally, Millennium Management LLC acquired a new equity stake in IsoPlexis during the fourth quarter worth approximately $7,392,000. Institutional investors hold 37.46% of the company’s shares.
IsoPlexis Company Profile (Get a rating)
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative drugs and personalized therapies in the United States, Canada, United Kingdom, Belgium, France, Czech Republic, Spain, in Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia and Korea.
Get a Free Copy of Zacks Research Report on IsoPlexis (ISO)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for IsoPlexis Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for IsoPlexis and related companies with MarketBeat.com’s FREE daily email newsletter.